Vyome Therapeutics, a clinical-stage healthcare company, announced its new Board of Directors set to take control of ReShape Lifesciences on August 15, 2025. The board, comprising MIT alumni and seasoned professionals with strong AI and industrial expertise, will replace the existing ReShape team as the company prepares for a public listing. The newly formed entity will be named Vyome Holdings, Inc. and will trade under the ticker symbol HIND. The board aims to align closely with shareholders and is focused on leveraging AI within healthcare and other traditional industries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812232598) on August 12, 2025, and is solely responsible for the information contained therein.